October 1, 2014: It’s never been hotter to do biotech business in Texas. Boasting 3,600 firms engaged in biotech R&D and manufacturing, the state has seen itself become the “Third Coast” of biotech as companies flock to do deals in the tax-friendly climate and pro-business environment.
October 1, 2014: Allergan has reportedly leased a 90,000 square-foot facility in North Austin, Texas but has not said why or what it plans to use the space for in the future. The news had biotech watchers speculating whether the company could be expanding operations.
October 1, 2014: Boehringer Ingelheim will invest more than €100 million (about $127 million U.S.) at its Dortmund location in order to expand manufacturing capabilities for its Respimat inhaler. This expansion is expected to create 100 new jobs at that site.
October 1, 2014: Valeant Pharmaceuticals received a Warning Letter from the U.S. FDA about its Bridgewater, New Jersey facility. In June 2014, the FDA inspected Valeant’s records related to the company’s Sculptra Aesthetic Injectable, which in July 2014 was divested to Galderma S.A.